Literature DB >> 18721766

Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.

Laurent Boissel1, Hande H Tuncer1, Monica Betancur1, Adam Wolfberg2, Hans Klingemann3.   

Abstract

Natural killer (NK) cell-mediated cytotoxicity can control leukemia relapse while protecting patients from graft-versus-host disease (GVHD) after allogeneic stem cell transplant. Cord blood (CB) is rich in NK cell progenitors with similar properties of proliferation and cytotoxicity as adult blood NK cells. Hence, it is attractive to expand and potentially utilize these cells for adoptive immunotherapy. In this study, CB mononuclear cells were CD3-depleted by immunomagnetic microbead selection to remove T cells. This CD3(dep) CB-MNC fraction was then plated for ex vivo expansion, with or without a feeder layer of irradiated umbilical cord mesenchymal stem cells (UC-MSC), with or without cytokines that have been shown to be critical for NK expansion: IL-2, IL-15, IL-3, and FLT-3L. At an average of 2 weeks of culture, there was significantly higher expansion (64.7 +/- 8.4-fold) of CD56(+)/CD3(-) NK cells in the presence of the UC-MSC feeder layer and cytokines compared to controls (no increase with feeder layer only and 6.4 +/- 1.5-fold increase with cytokines only, P < .05). Contact between CD3(dep) CB-MNC cells and UC-MSC augmented NK expansion. The combination of all 4 cytokines was superior to IL-2 alone or 2 cytokines combinations: mean 64.7 +/- 8.4-fold expansion with 4 cytokines combination versus IL-2 alone, IL-2 + FLT-3L, IL-2 + IL-15 or IL-2 + IL-3 (12.2 +/- 2.0, 14.4 +/- 2.4, 10.4 +/- 4.1, 25.2 +/- 8.1 respectively). We also observed that only fresh CD3(dep) CB-MNC preparations could be expanded reliably, whereas frozen and thawed CD3(dep) CB-MNC cells did not expand consistently (mean fold increase 6.5 +/- 3.2). Cytotoxicity of expanded NK cells was compared with NK cells from fresh and overnight IL-2 activated CD3(dep) CB-MNC. Whereas fresh cells displayed no discernible killing, strong cytotoxicity against K562, Raji, REH, and SUP-B15 cells lines was noted after overnight activation in IL-2. Cytotoxicity of expanded NK cells against Raji, REH, and SUP-B15 was lower, which, however, correlated with a predominant expansion of CD56(+)/CD16(-) cells known to have less cytolytic activity than CD56(+)/CD16(+). To test the transfection efficiency in NK cells, fresh or expanded CD3(dep) CB-MNC cells were electroporated with either DNA or mRNA constructs for GFP. DNA had a low transfection efficiency (<10%), whereas the one for mRNA reached 52%, but at the cost of significant cell death. Our results suggest that CB NK cell progenitors can be expanded to obtain large numbers by using an irradiated feeder of UC-MSC. They maintain an elevated cytotoxic profile, and may be genetically manipulated-all characteristics that make them suitable for cellular therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721766     DOI: 10.1016/j.bbmt.2008.06.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  41 in total

1.  Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Authors:  Hans Klingemann; Carrie Grodman; Elliott Cutler; Marvin Duque; Diane Kadidlo; Andreas K Klein; Kellie A Sprague; Kenneth B Miller; Raymond L Comenzo; Tarun Kewalramani; Neng Yu; Richard A Van Etten; David H McKenna
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

Review 2.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

3.  Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.

Authors:  L Zazzeroni; G Lanzoni; G Pasquinelli; C Ricordi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2017-09-29

4.  Mesenchymal Stem Cells - Sources and Clinical Applications.

Authors:  Hans Klingemann; David Matzilevich; James Marchand
Journal:  Transfus Med Hemother       Date:  2008-07-21       Impact factor: 3.747

5.  Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.

Authors:  Karen Bieback; Irena Brinkmann
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

Review 6.  T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.

Authors:  C Russell Cruz; Catherine M Bollard
Journal:  Haematologica       Date:  2015-06       Impact factor: 9.941

7.  A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Authors:  Giovanni F Torelli; Carmela Rozera; Laura Santodonato; Nadia Peragine; Giuseppina D'agostino; Enrica Montefiore; Maria R Napolitano; Domenica M Monque; Davide Carlei; Paola Mariglia; Simona Pauselli; Maria Gozzer; Mahnaz Shafii Bafti; Gabriella Girelli; Anna Guarini; Filippo Belardelli; Robin Foà
Journal:  Blood Transfus       Date:  2015-01-30       Impact factor: 3.443

8.  Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Authors:  Laurent Boissel; Monica Betancur; Winfried S Wels; Hande Tuncer; Hans Klingemann
Journal:  Leuk Res       Date:  2009-01-14       Impact factor: 3.156

9.  Mesenchymal stem cells in autoimmune diseases: hype or hope?

Authors:  Hans U Scherer; Melissa van Pel; René E M Toes
Journal:  Arthritis Res Ther       Date:  2010-06-18       Impact factor: 5.156

10.  Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells.

Authors:  Giuseppina Bonanno; Andrea Mariotti; Annabella Procoli; Maria Corallo; Giovanni Scambia; Luca Pierelli; Sergio Rutella
Journal:  BMC Immunol       Date:  2009-08-27       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.